NCT04486885

European Study of Cerebral Aspergillosis Treated With Isavuconazole

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 41 (actual)
• Sponsor: Imagine Institute · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Study clinical context Cerebral aspergillosis (CA) is a rare location of invasive aspergillosis (IA), associated with a high morbidity and mortality. Since 2002, voriconazole is the recommended first line treatment of invasive aspergillosis. More recently, isavuconazole appeared to be not less effective than voriconazole in the treatment of filamentous IFI, with a better tolerance profile. The investigators aim to evaluate better the efficacy and the safety of isavuconazole in the treatment of cerebral aspergillosis by a descriptive, multicentric, international retrospective cohort study.

Conditions

• Cerebral Aspergillosis
• Invasive Aspergillosis

Timeline

• Start date: 2021-08-01
• Primary completion: 2022-08-01
• Completion: 2023-03-01
• First posted: 2020-07-27
• Last updated: 2025-04-30

Locations

1 site across 1 country: France